Title:
NOVEL USE OF PYRIMIDINE DERIVATIVE COMPRISING LRRK KINASE INHIBITOR AS EFFECTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2020/040591
Kind Code:
A1
Abstract:
The present invention relates to a novel use of a pyrimidine derivative comprising an LRRK kinase inhibitor as an effective ingredient. A pharmaceutical composition, provided according to one aspect of the present invention, for prevention or treatment of at least one selected from pancreatic cancer, breast cancer, and lung cancer exhibits an excellent therapeutic effect on cancer in vitro and in vivo and, as such, can be advantageously used as a therapeutic agent for pancreatic cancer, breast cancer, and lung cancer.
Inventors:
CHOI HWAN GEUN (KR)
PARK JONG BAE (KR)
KO EUNHWA (KR)
SON JUNG BEOM (KR)
KIM NAM DOO (KR)
LEE SEUNG HOON (KR)
NAM DO-HYUN (KR)
PARK JONG BAE (KR)
KO EUNHWA (KR)
SON JUNG BEOM (KR)
KIM NAM DOO (KR)
LEE SEUNG HOON (KR)
NAM DO-HYUN (KR)
Application Number:
PCT/KR2019/010759
Publication Date:
February 27, 2020
Filing Date:
August 23, 2019
Export Citation:
Assignee:
DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR)
NAT CANCER CT (KR)
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR)
NAT CANCER CT (KR)
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR)
International Classes:
C07D213/12; A61K31/415; A61K31/437; A61K31/506; C07D239/30; C07D401/12; C07D403/12; C07D407/14; C07D409/04; C07D487/04
Domestic Patent References:
| WO2008075007A1 | 2008-06-26 |
Foreign References:
| KR20150027267A | 2015-03-11 | |||
| US20170209460A1 | 2017-07-27 |
Other References:
HENDERSON, J. L.: "Discovery and Preclinical Profiling of 3-[4-(Morpholin -4-yl)-7H-pyrrolo[2,3-d]pyrirnidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor", J. MED. CHEM., 2015, XP055687675
WILLIAMSON, D. S.: "Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1)", J. MED. CHEM., vol. 60, pages 8945 - 8962
WILLIAMSON, D. S.: "Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1)", J. MED. CHEM., vol. 60, pages 8945 - 8962
Attorney, Agent or Firm:
LEE, Won Hee (KR)
Download PDF:
Previous Patent: CORELESS CONTACTLESS CURRENT MEASUREMENT SYSTEM
Next Patent: DILATOR WITH ADJUSTABLE DIAMETER
Next Patent: DILATOR WITH ADJUSTABLE DIAMETER